Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543955 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL31589 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL10324073 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL28532 | 1.00 | CYP3A4 (0.39) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL15978095 | 0.91 | CYP3A4 (0.37) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL14067502 | 0.87 | CYP3A4 (0.41) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL9309105 | 0.87 | CYP3A4 (0.41) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL9308091 | 0.87 | CYP3A4 (0.41) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL22088075 | 0.87 | CYP3A4 (0.33) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 | |
| SCHEMBL9701371 | 0.85 | CYP3A4 (0.39) | CYP3A4TDP1TAAR1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117209375-A | Preparation method of polysubstituted chiral adipic acid compound containing quaternary carbon center | 四川大学 | 2023-12-12 | — | — | CN | claimed |
| CN-115746037-A | Synthetic method of alpha-halogenated borate compound and product thereof | 同济大学 | 2023-03-07 | — | — | CN | claimed |
| CN-113087742-B | Phosphine chiral center containing compound, organic transition metal complex and preparation method thereof | 中国科学技术大学 | 2022-05-13 | — | — | CN | claimed |
| CN-111718250-B | Method for preparing R-citronellal | 万华化学集团股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-114262345-A | Synthesis method of novel phosphine-centered chiral compound | 中国科学技术大学 | 2022-04-01 | — | — | CN | claimed |
| US-7638628-B2 | for the reduction of ketones to alcohols via hydrogen transfer; reduction catalysts; hydrogenation catalysts | UNIVERSITA' DEGLI STUDI DI UDINE (IT) | 2009-12-29 | — | — | US | claimed |
| US-20080249308-A1 | Complexes of Ruthenium with 2-(Aminomethyl)Pyridines and Phosphines, their Preparation and Use as Catalysts | UNIVERSITA'DEGLI STUDI DI UDINE (IT) | 2008-10-09 | — | — | US | claimed |
| EP-1747224-B1 | COMPLEXES OF RUTHENIUM WITH 2-(AMINOMETHYL)PYRIDINES AND PHOSPHINES, THEIR PREPARATION AND USE AS CATALYSTS | UNIV DEGLI STUDI UDINE (IT) | 2008-07-16 | — | — | EP | claimed |
| EP-1801093-A1 | Process for the Preparation of enantiomer-enriched 2-Alkoxy-3-Phenyl-Propionic Acid | Saltigo GmbH (DE) | 2007-06-27 | — | — | EP | claimed |
| EP-1747224-A1 | COMPLEXES OF RUTHENIUM WITH 2-(AMINOMETHYL)PYRIDINES AND PHOSPHINES, THEIR PREPARATION AND USE AS CATALYSTS | Universita' Degli Studi di Udine (IT) | 2007-01-31 | — | — | EP | claimed |
| WO-2005105819-A1 | COMPLEXES OF RUTHENIUM WITH 2-(AMINOMETHYL)PYRIDINES AND PHOSPHINES, THEIR PREPARATION AND USE AS CATALYSTS | UNIVERSITA' DEGLI STUDI DI UDINE (IT) | 2005-11-10 | — | — | WO | claimed |
| EP-0631571-B1 | PREPARATION OF OPTICALLY ACTIVE HYDRAZINES AND AMINES | DU PONT (US) | 1997-06-04 | — | — | EP | claimed |
| US-5426223-A | Hydrogenation of n-acyl hydrazones in presence of catalyst comprising complex pf transition metal bonded to phosphine ligands | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-06-20 | — | — | US | claimed |
| US-5250731-A | Asymmetric hydrogenation of N-acylhydrazones to N-acylhydrazines in presence of chiral phospholane complex | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-10-05 | — | — | US | claimed |
| WO-1993019040-A1 | PREPARATION OF OPTICALLY ACTIVE HYDRAZINES AND AMINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-09-30 | — | — | WO | claimed |
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CURIA SPAIN S A U (ES) | 2026-05-21 | — | — | US | disclosed |
| US-20260049079-A1 | CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-02-19 | — | — | US | disclosed |
| EP-0631571-A1 | PREPARATION OF OPTICALLY ACTIVE HYDRAZINES AND AMINES. | DU PONT (US) | 1995-01-04 | — | — | EP | disclosed |
| US-5250731-A | Asymmetric hydrogenation of N-acylhydrazones to N-acylhydrazines in presence of chiral phospholane complex | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| WO-1993019040-A1 | PREPARATION OF OPTICALLY ACTIVE HYDRAZINES AND AMINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | JAK1, JAK3, JAK2 | CYP3A4 2751/4885TDP1 4291/4885TAAR1 2009/4885 |
| US-20080249308-A1 | Complexes of Ruthenium with 2-(Aminomethyl)Pyridines and Phosphines, their Preparation and Use as Catalysts | ADH5, PDK2, PDK1 | CYP3A4 425/4885TDP1 1771/4885TAAR1 106/4885 |
| US-20260049079-A1 | CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS | BRAF, HRAS, RAF1 | CYP3A4 2184/4885TDP1 597/4885TAAR1 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.